Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia Academic Article uri icon

Overview

MeSH Major

  • Enzyme Inhibitors
  • Fusion Proteins, bcr-abl
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Piperazines
  • Protein-Tyrosine Kinases
  • Pyrimidines

abstract

  • STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed. Our results provide evidence of the essential role of BCR-ABL tyrosine kinase activity in CML and demonstrate the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.

publication date

  • April 5, 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJM200104053441401

PubMed ID

  • 11287972

Additional Document Info

start page

  • 1031

end page

  • 7

volume

  • 344

number

  • 14